Clearside Biomedical Inc CLSD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CLSD is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $1.41
- Day Range
- $1.35–1.48
- 52-Week Range
- $0.65–2.12
- Bid/Ask
- $1.35 / $1.42
- Market Cap
- $102.37 Mil
- Volume/Avg
- 231,875 / 399,132
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 10.59
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 30
- Website
- https://www.clearsidebio.com
Comparables
Valuation
|
Metric
|
CLSD
|
ACLX
|
PTGX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 5.60 | 4.39 |
Price/Sales | 10.59 | 22.65 | 24.24 |
Price/Cash Flow | — | — | — |
Price/Earnings
CLSD
ACLX
PTGX
Financial Strength
|
Metric
|
CLSD
|
ACLX
|
PTGX
|
|---|---|---|---|
Quick Ratio | 4.27 | 5.94 | 16.54 |
Current Ratio | 4.42 | 6.06 | 16.71 |
Interest Coverage | −2.47 | −23.39 | — |
Quick Ratio
CLSD
ACLX
PTGX
Profitability
|
Metric
|
CLSD
|
ACLX
|
PTGX
|
|---|---|---|---|
Return on Assets (Normalized) | −69.45% | −6.26% | −16.60% |
Return on Equity (Normalized) | — | −12.08% | −18.20% |
Return on Invested Capital (Normalized) | — | −13.11% | −23.45% |
Return on Assets
CLSD
ACLX
PTGX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wkmdlvvjh | Ddjp | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Frbcbgz | Tqxypcd | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Myywnvx | Qmzbqw | $98.8 Bil | |
MRNA
| Moderna Inc | Bwwxsdr | Cfxrc | $38.8 Bil | |
ARGX
| argenx SE ADR | Xxmgztrnq | Hhlg | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Vpzqnqh | Cvcb | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vhrmhvny | Dwjnmj | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ltydndmf | Xsmwwwq | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zldwqhphmr | Myypq | $12.4 Bil | |
INCY
| Incyte Corp | Hhxzzqyj | Sbkghb | $11.9 Bil |